甾体或非甾体盐皮质激素受体拮抗剂:是否仍需通过钾结合剂来维持肾素-血管紧张素-醛固酮系统抑制剂的使用?
肾素-血管紧张素-醛固酮系统抑制剂(RAASi)和盐皮质激素受体拮抗剂(MRAs)可改善慢性肾脏病和心力衰竭患者的结局,但高钾血症限制了其使用。非甾体MRA非奈利酮较甾体MRA螺内酯的高钾血症风险更低。新型钾结合剂(帕替罗姆、环硅酸锆钠)可管理高钾血症并维持RAASi和MRAs治疗,但尚无研究评估其对心血管事件等临床终点的影响;由于费用、可及性、服药负担和患者选择等限制,替代策略可能更实用。
要点
- RAASi和MRAs改善CKD和心衰结局,但高钾血症限制其使用。
- 一项试验显示非奈利酮较螺内酯的高钾血症风险更低。
- 钾结合剂可管理高钾血症并维持RAASi/MRAs,但未评估对心血管事件的影响。
核心结论
- 非甾体MRAs可能较甾体MRAs的高钾血症风险更低,且具有更强的抗炎和抗纤维化作用,从而降低肾脏疾病进展风险。
- SGLT2抑制剂也可降低使用MRAs患者的高钾血症风险,并减少心血管事件和肾脏疾病进展。
- 这些可能作为更好的第一线干预措施,以避免对钾结合剂的需求并提供额外获益。
研究设计与样本
- 综述类文章,检索范围未报告。
主要发现
- 一项试验显示,与甾体MRA螺内酯相比,新型非甾体MRA非奈利酮的高钾血症风险更低。
- 多项研究显示,与安慰剂相比,钾结合剂在预防高钾血症或甾体MRA停药方面有效。
- 尚无研究评估钾结合剂策略是否影响心血管事件等临床重要终点。
关键数值与推荐
- 钾结合剂(包括帕替罗姆和环硅酸锆钠)在胃肠道腔内结合游离钾离子,阻止膳食钾吸收并增加钾分泌。
- 保守策略包括加强监测和使用袢利尿剂或噻嗪类利尿剂以增加尿钾排泄。
临床怎么用
- 由于缺乏对临床重要终点的评估,以及费用、临床可及性、服药负担和患者选择等相关限制,替代的潜在策略可能更实用。
局限性
- 尚无研究评估钾结合剂策略是否影响心血管事件等临床重要终点。
- 钾结合剂存在费用、临床可及性、服药负担和患者选择等相关限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Renin-angiotensin-aldosterone system inhibitors (RAASi) and mineralocorticoid receptor antagonists (MRAs) are important interventions to improve outcomes in patients with chronic kidney disease and heart failure, but their use is limited in some patients by the development of hyperkalemia. The risk of hyperkalemia may differ between agents, with one trial showing lower risk of hyperkalemia with the novel non-steroidal MRA finerenone compared with steroidal MRA spironolactone. Novel potassium binders, including patiromer and sodium zirconium cyclosilicate, are available interventions to manage hyperkalemia and enable continuation of RAASi and MRAs in patients who could benefit from these treatments. These agents bind free potassium ions in the lumen of the gastrointestinal tract to prevent the absorption of dietary potassium and increase potassium secretion. Several studies showed that potassium binders are effective compared with placebo for preventing hyperkalemia or steroidal MRA discontinuation, but none has evaluated whether this strategy impacts clinically important endpoints such as cardiovascular events. Due to this and other limitations related to cost, clinical availability, pill burden and patient selection, alternative potential strategies to mitigate hyperkalemia may be more practical. Conservative strategies include increased monitoring and use of loop or thiazide diuretics to increase urinary potassium excretion. Non-steroidal MRAs may have a lower risk of hyperkalemia than steroidal MRAs and have stronger anti-inflammatory and anti-fibrotic effects with resultant reduced risk of kidney disease progression. Sodium-glucose cotransporter-2 inhibitors also decrease hyperkalemia risk in patients on MRAs and decrease cardiovascular events and kidney disease progression. These may be better first-line interventions to obviate the need for potassium binders and offer additional benefits.
引用
- Gregg LP, Navaneethan SD. Steroidal or non-steroidal MRAs: should we still enable RAASi use through K binders? Nephrol Dial Transplant. 2023. PMID: 36264349. doi:10.1093/ndt/gfac284
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。